HLA-C and cancer: Compared to CART therapy, autologous engineered TCRs (TCR-Ts) allow for targeting of intracellular peptides like cancer testis antigens (CTAs), as they are presented by antigen-presenting cells (APCs) via the major histocompatibility complex (MHC) to TCRs [11].